Effects of an Opioid Free/Sparing Care Pathway for Patients Undergoing Obesity Surgery

The intervention group will obtain the pharmacological treatment during both perioperative. Pharmacological treatment in the intervention group differs solely from the patients in the control group by replacing opioids with the following non-opioid treatment:

The intervention tests non-pharmacological interventions compared to conventional treatment, supplemented by an evidenced-based Person-centred care PCC approach throughout the continuum of the perioperative and until 4 weeks after discharge. This will be part of patients in Phase 2

The intervention group will obtain the pharmacological treatment perioperatively. Pharmacological treatment in the intervention group differs solely from the patients in the control group by replacing opioids with the following non-opioid treatment:

The intervention group will obtain the pharmacological treatment perioperatively. Pharmacological treatment in the intervention group differs solely from the patients in the control group by replacing opioids with the following non-opioid treatment.

The intervention group will obtain non-pharmacological treatment by TENS during the entire hospital stay (both perioperative and post-operative) until discharge.

The control group receives general anesthesia with Remifentanil as the routine opioid drug during general anesthesia.

The patient receives general anesthesia with Desflurane as the routine volatile anesthetic during general anesthesia

The patient receives general anesthesia with Propofol as the routine induction anaesthetic during general anesthesia

The control group receives Oxycodone as the routine pain management drug post-operative.